Core Viewpoint - The company has entered into exclusive collaboration agreements for two monoclonal antibody injections, GR2001 and GR1801, with subsidiaries of Kangzhe Pharmaceutical and RXILIENT MEDICAL, indicating a strategic move to enhance its product portfolio and market presence in specific regions [1] Group 1 - The company will receive upfront payments and milestone payments as part of the collaboration agreements [1] - Kangzhe Pharmaceutical will obtain exclusive commercialization rights for the two products in mainland China [1] - RXILIENT MEDICAL will gain exclusive licensing rights for the products in the Asia-Pacific region, as well as the Middle East and North Africa [1]

证券之星消息，9月19日，智翔金泰（688443）融资买入1435.15万元，融资偿还1223.5万元，融资净买 入211.66万元，融资余额1.39亿元，近3个交易日已连续净买入累计2716.21万元，近20个交易日中有14 个交易日出现融资净买入。 融资融券余额1.39亿元，较昨日上涨1.59%。 | 交易日 | 两融余额(元) | 余额变动(元) | 变动幅度 | | --- | --- | --- | --- | | 2025-09-19 | 1.39亿 | 217.92万 | 1.59% | | 2025-09-18 | 1.37亿 | 1495.44万 | 12.24% | | 2025-09-17 | 1.22亿 | 1009.57万 | 9.01% | | 2025-09-16 | 1.12亿 | 577.75万 | 5.44% | | 2025-09-15 | 1.06亿 | 729.87万 | 7.38% | | 交易日 | 融资净买入(元) | 融资余额(元) | 占流通市值比 | | --- | --- | --- | --- | | 2025-09-19 | 211.66万 | 1. ...

此前几日，智翔金泰在新药研发上取得重大进展。9月11日晚间，公司公告称，其"泰利奇拜单抗注射液 (GR1802注射液)"用于成人中、重度特应性皮炎适应症III期临床试验达到主要终点指标，且已向国家药 品监督管理局(NMPA)药品审评中心(CDE)提交该适应症新药上市申请并获受理。此外，在感染性疾病 治疗领域，智翔金泰自主研发的全球首个狂犬病被动免疫双特异性抗体GR1801(斯乐韦米单抗)注射液 和抗破伤风毒素单克隆抗体GR2001注射液，均已向CDE提交新药上市申请，且已顺利获得受理，有望 为狂犬病和破伤风的治疗带来新突破。 智翔金泰是一家创新驱动型生物制药企业，自2015年成立以来，专注于抗体药物的研发、生产及商业 化，业务涵盖自身免疫性疾病、感染性疾病和肿瘤等重大疾病领域。目前，公司拥有在研产品14个，凭 借自主研发构建起六大核心技术平台，为持续创新提供技术支撑。此次多款新药上市申请获受理，以及 参与行业业绩说明会，彰显了公司在创新药研发领域的实力和积极与投资者沟通的态度。 中证报中证网讯(王珞)9月16日，智翔金泰(688443)参加2025年半年度科创板创新药行业集体业绩说明 会，此次会议通过上海证券 ...

Core Points - The company will participate in the 2025 Investor Online Collective Reception Day and Semi-Annual Performance Briefing on September 25, 2025, to enhance investor relations and corporate governance [1][2] - The company has received approval from the National Medical Products Administration for the clinical trial of its product GR2301 injection, which is aimed at treating vitiligo [4][5] - GR2301 injection is a recombinant fully human anti-IL-15 monoclonal antibody developed by the company, targeting autoimmune diseases caused by IL-15 expression disorders [6][7] Group 1 - The event will be held online, allowing investors to interact with the company's senior management from 15:00 to 17:00 on the specified date [1][2] - The clinical trial approval for GR2301 injection indicates compliance with relevant drug registration requirements, allowing the company to proceed with its clinical trials [4][5] - There are currently no approved antibody drugs targeting IL-15 globally, highlighting the potential market opportunity for GR2301 injection [7] Group 2 - The company emphasizes its commitment to transparency and legal responsibility regarding the accuracy and completeness of the information disclosed [1][4] - The GR2301 injection is classified as a Class 1 therapeutic biological product, indicating its innovative nature and potential high value in the market [5][6] - The company will continue to follow regulatory requirements and disclose further developments regarding the clinical trial and product registration process [8]

Core Points - The company Zhixiang Jintai announced that it has received approval from the National Medical Products Administration for the clinical trial of its product GR2301 injection [2] Group 1 - The clinical trial application for GR2301 injection has been approved [2]

Core Viewpoint - The company, Zhixiang Jintai (688443.SH), has received approval from the National Medical Products Administration for the clinical trial of its product GR2301 injection, a recombinant fully human anti-IL-15 monoclonal antibody aimed at treating autoimmune diseases like vitiligo caused by IL-15 expression imbalance [1] Group 1 - The clinical trial application for GR2301 injection has been approved, marking a significant milestone for the company [1] - GR2301 injection is designed to inhibit the downstream IAK-STAT signaling pathway by blocking IL-15 interactions, which is crucial for treating autoimmune diseases [1] - As of the announcement date, there are no approved antibody drugs targeting IL-15 globally, indicating a potential market opportunity for the company [1]

证券代码：688443 证券简称：智翔金泰 公告编号：2025-042 重庆智翔金泰生物制药股份有限公司 自愿披露关于GR2301注射液获得药物临床试验 批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 注册分类：治疗用生物制品 1 类 申请事项：境内生产药品注册临床试验 申请人：重庆智翔金泰生物制药股份有限公司 受理号：CXSL2500569 适应症：白癜风 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，GR2301 注射液临床试验申请符合药品注册的有关要求，同意本品开展临床试验。 二、药品其他相关情况 近日，重庆智翔金泰生物制药股份有限公司（以下简称"公司"）收到国家 药品监督管理局核准签发的《药物临床试验批准通知书》，公司在研产品 GR2301 注射液的临床试验申请获得批准。现将相关情况公告如下： 一、药品基本信息 药品名称：GR2301 注射液 三、风险提示 根据国家药品注册管理相关法规，该药品完成临床试验后还需提交新药上市 申请，取得药品注册证书后才可上市销售。 创新药产品具有高科技、 ...

为进一步提高辖区上市公司投资者关系管理水平，促进公司完善公司治理， 助力上市公司高质量发展，在重庆证监局指导下，重庆上市公司协会联合深圳市 全景网络有限公司举办辖区上市公司 2025 年投资者网上集体接待日暨半年度业 绩说明会活动。 重庆智翔金泰生物制药股份有限公司（以下简称"公司"）将参加本次投资 者网上集体接待日暨半年度业绩说明会活动。本次活动采用网络远程的方式举行， 投资者可登录"全景路演"网站（https://rs.p5w.net）参与本次活动，活动时间为 2025 年 9 月 25 日（星期四）下午，其中公司与投资者线上互动交流的时间为 15:00-17:00。 证券代码：688443 证券简称：智翔金泰 公告编号：2025-041 重庆智翔金泰生物制药股份有限公司 关于参加重庆辖区上市公司 2025 年投资者网上集体 接待日暨半年度业绩说明会活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 届时，公司相关高级管理人员将参加本次活动，就投资者关心的问题，与投 资者进行在线沟通与交流，欢迎广大投资者踊跃参 ...

Core Viewpoint - The company, Zhixiang Jintai (688443.SH), has received approval from the National Medical Products Administration for the clinical trial of its product GR2301 injection, which is a recombinant fully human anti-IL-15 monoclonal antibody aimed at treating autoimmune diseases like vitiligo caused by IL-15 expression disorders [1] Group 1 - The clinical trial application for GR2301 injection has been approved [1] - GR2301 injection is developed independently by the company [1] - The mechanism of GR2301 involves blocking IL-15 interactions, which may help in treating autoimmune diseases [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the clinical trial of its product GR2301 injection, which is a recombinant fully human anti-IL-15 monoclonal antibody aimed at treating autoimmune diseases like vitiligo caused by IL-15 expression dysregulation [1] Group 1 - The clinical trial application for GR2301 injection has been approved [1] - GR2301 injection is developed independently by the company [1] - The mechanism of GR2301 involves blocking IL-15 from binding to its receptors, thereby inhibiting the downstream IAK-STAT signaling pathway [1]